NEW YORK – Sophia Genetics and Hitachi said on Thursday that they have signed a long-term collaboration deal to extend data-driven precision medicine to healthcare providers and pharmaceutical companies worldwide.
The companies said that they would initially cooperate to expand the reach of Sophia's core DDM analytics platform and various Hitachi digital healthcare offerings, including its molecular tumor board support service, in "key geographies." They also hope to collaborate on secure personal genomics data management, data-driven clinical decision support, and the acceleration of drug development in oncology and other areas, as well as to codevelop new products in the longer term.
"This partnership will enable us to broaden our commercial reach and support improved health outcomes for more patients," Jurgi Camblong, CEO of Lausanne, Switzerland-based Sophia, said in a statement.
"Hitachi is excited to start [a] long-term partnership with Sophia Genetics to co-create innovative solutions for improving quality of life of patients by leveraging both companies' data analytics and AI technologies," added Keiji Kojima, executive VP and executive officer of Hitachi and general manager of its Smart Life Business Management Division.
Hitachi's investment arm, Hitachi Ventures, already has an equity stake in Sophia. The Japanese firm co-led a $110 million investment round in Sophia last year.